harvoni- ledipasvir and sofosbuvir tablet, film coated harvoni- ledipasvir and sofosbuvir tablet, film coated harvoni- ledipas
gilead sciences, inc - ledipasvir (unii: 013te6e4wv) (ledipasvir - unii:013te6e4wv), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - ledipasvir 90 mg - harvoni is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis c virus (hcv) [see dosage and administration (2.2 and 2.3) and clinical studies (14)] : - genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis - genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin - genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin if harvoni is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and administration (2.2)] . risk summary if harvoni is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. refer to the ribavirin prescribing information for more information on ribav
harvoni access- ledipasvir and sofosbuvir tablet, film coated
gilead sciences, inc - ledipasvir (unii: 013te6e4wv) (ledipasvir - unii:013te6e4wv), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - ledipasvir 90 mg - adult patients : harvoni is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration (2.2) and clinical studies (14)] : - genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis - genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin - genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin pediatric patients : harvoni is indicated for the treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with hcv genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis [see dosage and administration (2.3) and clinical studies (14.6)] . if harvoni is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and ad
harvoni tablets ledipasvir 90 mg/ sofosbuvir 400 mg
gilead sciences, inc, usa - ledipasvir 90mg/sofosbuvir 400mg - tablets - ledipasvir 90 mg/ sofosbuvir 400 mg
vosevi film-coated tablets 400mg100mg100mg
gilead sciences singapore pte. ltd. - sofosbuvir; velpatasvir; voxilaprevir - tablet, film coated - sofosbuvir 400 mg; velpatasvir 100 mg; voxilaprevir 100 mg
epclusa tablet 400mg100mg
gilead sciences singapore pte. ltd. - sofosbuvir; velpatasvir - tablet, film coated - sofosbuvir 400mg; velpatasvir 100mg
velsof tablets film-coated
m/s hetero labs ltd. - sofosbuvir, velpatasvir - tablets film-coated - 400mg+ 100mg
myhep tablets
mylan laboratories limited, india - sofosbuvir - tablets
harvoni (ledipasvir 90mgsofosbuvir 400mg) film-coated tablets
gilead sciences malaysia sdn. bhd. - sofosbuvir; ledipasvir -
buvir-lp film-coated tablet
ledispavir acetone solvate/ sofosbuvir - film-coated tablet - ledispavir acetone solvate 90mg, sofosbuvir 300mg - sofosbuvir and ledipasvir
sovaldi film-coated tablet
sofosbuvir - film-coated tablet - 400mg sofosbuvir - other antivirals for systemic use